Metformin Plus IUD Well-Tolerated in EIN/Endometrial Cancer
A slightly higher complete response rate was observed with the metformin regimen vs with the levonorgestrel-releasing IUD alone in endometrial cancer.
Cancer Vaccine/Durvalumab Yields Efficacy in HPV+ Cervical Cancer
Results from the phase 2 DURBAC trial showed BVAC-C/durvalumab improved response in HPV+ cervical cancer.
Luveltamab Tazevibulin Elicits Response in Platinum-Resistant Ovarian Cancer, Low/Medium FRα Expression
The REFRαME-O1 trial improved response in patients with FRα–positive platinum-resistant ovarian cancer, including those with low to medium expression when given luveltamab tazevibulin.
Hysteroscopic Resection Safely Preserves Fertility in Endometrial Cancer
No deaths or significant adverse effects were reported in the screened population among those who received hysteroscopic resection for endometrial cancer.
Mirvetuximab Soravtansine Sustains OS Benefit in FRα+ PROC
Mirvetuximab soravtansine additionally showcased PFS, ORR, and DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.
Avutometinib/Defactinib Shows Promise in Advanced Mesonephric Gynecologic Cancer
The phase 2 trial is currently accruing additional patients with advanced mesonephric gynecologic cancer for treatment with avutometinib/defactinib.
Pembrolizumab/Olaparib Yields PFS Significance in Advanced Ovarian Cancer
The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.
Zimberelimab Combo Elicits Activity in Previously Treated Cervical Cancer
Combining zimberelimab with lenvatinib produced a manageable safety profile among patients with advanced cervical cancer in a phase 2 trial.
Afuresertib/Paclitaxel Shows No Survival Difference vs Paclitaxel in PROC
Although there was no statistical significance in survival data, afuresertib/paclitaxel improved PFS vs paclitaxel in patients with the pAKT biomarker.
Cadonilimab Combo Shows Encouraging Activity in Advanced Endometrial Cancer
Cadonilimab plus lenvatinib appeared to have a manageable safety profile in a phase 2 trial.
Chemoradiation Reduces Short-Term QOL vs Radiation Alone in Cervical Cancer
Despite similar 36-week results, chemoradiation showed a statistically significant difference in QOL scores at 3 and 7 weeks vs radiation therapy alone.
Olaparib Combo Enhances PFS Across pMMR Endometrial Cancer Subgroups
Adding maintenance olaparib to durvalumab/chemotherapy in pMMR endometrial cancer improved PFS among those with detectable ctDNA at baseline.
Pembrolizumab/CCRT Yields Significant Efficacy in Advanced Cervical Cancer
Second interim analysis results from the KEYNOTE-A18 trial show continued efficacy of pembrolizumab/CCRT in those with locally advanced cervical cancer.
ET Shows Favorable Physical Health Decline Data vs Chemo in Breast Cancer
Endocrine therapy as a treatment for breast cancer showed similar long-lasting physical health decline data as what was seen in women who did not have breast cancer.
Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma
Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.
Investigating the Emergence of Artificial Intelligence on Oncologic Practice
As artificial intelligence has arrived in the oncology field, experts discuss how this new technology can have implications for transforming clinical practice.
Insight Into COVID-19’s Impact On Cancer Care: 5 Years Later
Learn how COVID-19 impacted oncology practice from the uptake of telehealth to delays in screening, with key takeaways from leading oncologists.
EC Approved Liso-cel in Pretreated Relapsed/Refractory Follicular Lymphoma
Liso-cel has been approved by the European Commission for the treatment of adult patients with follicular lymphoma who received 2 or more prior lines of systemic therapy.
Radiation Oncology in Prostate Cancer Is Advancing Thanks to Technology and Time
“The better the systemic therapy, immunotherapy, or targeted therapy, the more important a non-invasive, local treatment will be,” James B. Yu stated.
Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers
Results from the CheckMate649 trial support the use of nivolumab plus chemotherapy in the treatment of advanced gastric cancers.
Durvalumab Is Not Statistically Significant Vs Cetuximab in HNSCC
The trial was terminated early due to no statistical significance observed between durvalumab and cetuximab for patients with head and neck squamous cell carcinoma.
Highlighting Developments and Informing Treatment Planning in CLL Care
Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.
A Glimpse at Practice-Shifting Presentations at The 2025 SGO Annual Meeting
The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.
New Cohort Approved in Phase 1/2 Trial of TTX-MC138 in Solid Cancers
Based on positive safety data from the third cohort, a safety review committee approved the opening of a fourth cohort as well as more enrollment into the third cohort.
Five-Year Impact of the COVID-19 Pandemic on the Oncology Community
Leading multidisciplinary oncology professionals look back at how the COVID-19 pandemic changed cancer care.
Strong Collaboration is Essential for Radiation Oncologists and Other Experts
As a radiation oncologist, James B. Yu, MD, MHS, FASTRO, works with urologists, medical oncologists, radiologists, pathologists, physicists, and health services researchers.
Immunotherapy/Radiation Shows Responses in NSCLC Brain Metastases
Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.
Considerations for Equity and Regulations for AI Tools in Oncology
Testing AI-powered tools globally across diverse patient groups may ensure that they are accurate and consistent for all patients.
Vepdegestrant Meets PFS Primary End Point in ESR1m ER+/HER2– Breast Cancer
The safety profile of vepdegestrant in ER–positive/HER2– breast cancer was consistent with its observed profile in previous studies.
AI Model May Predict Immunotherapy Responses in Advanced NSCLC
Use of Deep-IO may help refine treatment precision and identify patients with advanced NSCLC who are likely to benefit from immune checkpoint inhibitors.
